Uncategorized
Ranibizumab 0.5 mg effectively manages pigment epithelial detachment
Monthly or as-needed 0.5-mg injections of ranibizumab were effective in treating pigment epithelial detachment associated with neovascular age-related macular degeneration, according to a post hoc analysis of the HARBOR study.Visual acuity improved regardless of the status or height of pigment epithelial detachment (PED) at baseline. In addition, a 2-mg dose of Lucentis (ranibizumab, Genentech) led to a higher rate of PED resolution but offered no additional improvement in visual acuity.